NO310555B1 - Nye taxoider, deres fremstilling og farmasöytiske preparater inneholdende taxoidene - Google Patents

Nye taxoider, deres fremstilling og farmasöytiske preparater inneholdende taxoidene Download PDF

Info

Publication number: NO310555B1
Authority: NO; Norway
Prior art keywords: residue; general formula; acid; temperature; aliphatic
Prior art date: 1992-12-09

Application number

NO19952264A

Other languages

English (en)

Norwegian (no)

Other versions

NO952264D0 (no

NO952264L (no

Inventor

Herve Bouchard

Jean-Dominique Bourzat

Alain Commercon

Original Assignee

Rhone Poulenc Rorer Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-12-09

Filing date

1995-06-08

Publication date

2001-07-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9436375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO310555(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-06-08 Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa

1995-06-08 Publication of NO952264D0 publication Critical patent/NO952264D0/no

1995-06-08 Publication of NO952264L publication Critical patent/NO952264L/no

2001-07-23 Publication of NO310555B1 publication Critical patent/NO310555B1/no

Links

239000000825 pharmaceutical preparation Substances 0.000 title claims description 5
238000002360 preparation method Methods 0.000 title abstract description 16
-1 alkyl radical Chemical class 0.000 claims abstract description 70
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 43
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 14
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 72
150000001875 compounds Chemical class 0.000 claims description 62
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 53
150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 33
239000002253 acid Substances 0.000 claims description 30
239000003960 organic solvent Substances 0.000 claims description 30
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 29
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 27
150000002148 esters Chemical class 0.000 claims description 27
238000011282 treatment Methods 0.000 claims description 27
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
125000006239 protecting group Chemical group 0.000 claims description 23
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 22
229910052725 zinc Inorganic materials 0.000 claims description 21
239000011701 zinc Substances 0.000 claims description 21
229910052500 inorganic mineral Inorganic materials 0.000 claims description 20
239000011707 mineral Substances 0.000 claims description 20
150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 18
DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 18
150000002170 ethers Chemical class 0.000 claims description 17
125000000217 alkyl group Chemical group 0.000 claims description 16
150000002825 nitriles Chemical class 0.000 claims description 16
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 15
239000003795 chemical substances by application Substances 0.000 claims description 14
238000000034 method Methods 0.000 claims description 14
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 13
125000001931 aliphatic group Chemical group 0.000 claims description 13
229910052802 copper Inorganic materials 0.000 claims description 13
239000010949 copper Substances 0.000 claims description 13
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 12
150000002576 ketones Chemical class 0.000 claims description 12
150000007524 organic acids Chemical class 0.000 claims description 12
239000000203 mixture Substances 0.000 claims description 11
150000008064 anhydrides Chemical class 0.000 claims description 10
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 9
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 9
150000007522 mineralic acids Chemical class 0.000 claims description 9
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 8
230000003213 activating effect Effects 0.000 claims description 8
150000003927 aminopyridines Chemical class 0.000 claims description 8
229910052799 carbon Inorganic materials 0.000 claims description 8
125000004432 carbon atom Chemical group C* 0.000 claims description 8
150000004820 halides Chemical class 0.000 claims description 8
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 8
238000011065 in-situ storage Methods 0.000 claims description 7
150000007530 organic bases Chemical class 0.000 claims description 7
229910021529 ammonia Inorganic materials 0.000 claims description 6
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 6
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 6
ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 6
230000002378 acidificating effect Effects 0.000 claims description 5
125000003118 aryl group Chemical group 0.000 claims description 5
125000005843 halogen group Chemical group 0.000 claims description 5
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 4
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 claims description 4
150000001718 carbodiimides Chemical class 0.000 claims description 4
235000019253 formic acid Nutrition 0.000 claims description 4
230000008569 process Effects 0.000 claims description 4
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
125000004953 trihalomethyl group Chemical group 0.000 claims description 4
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 3
150000001298 alcohols Chemical class 0.000 claims description 3
125000003710 aryl alkyl group Chemical group 0.000 claims description 3
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
125000003107 substituted aryl group Chemical group 0.000 claims description 2
125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
150000004649 carbonic acid derivatives Chemical class 0.000 claims 3
150000003510 tertiary aliphatic amines Chemical class 0.000 claims 3
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims 1
238000009833 condensation Methods 0.000 claims 1
230000005494 condensation Effects 0.000 claims 1
QUQFTIVBFKLPCL-UHFFFAOYSA-L copper;2-amino-3-[(2-amino-2-carboxylatoethyl)disulfanyl]propanoate Chemical compound [Cu+2].[O-]C(=O)C(N)CSSCC(N)C([O-])=O QUQFTIVBFKLPCL-UHFFFAOYSA-L 0.000 claims 1
230000000259 anti-tumor effect Effects 0.000 abstract description 2
150000005840 aryl radicals Chemical class 0.000 abstract description 2
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 1
125000003342 alkenyl group Chemical group 0.000 abstract 1
125000000304 alkynyl group Chemical group 0.000 abstract 1
150000001602 bicycloalkyls Chemical group 0.000 abstract 1
125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
LEVJVKGPFAQPOI-UHFFFAOYSA-N phenylmethanone Chemical compound O=[C]C1=CC=CC=C1 LEVJVKGPFAQPOI-UHFFFAOYSA-N 0.000 abstract 1
150000003254 radicals Chemical class 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 84
239000000243 solution Substances 0.000 description 25
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 24
239000000047 product Substances 0.000 description 20
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 13
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
235000010755 mineral Nutrition 0.000 description 12
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
239000002609 medium Substances 0.000 description 10
239000012074 organic phase Substances 0.000 description 10
239000000377 silicon dioxide Substances 0.000 description 10
235000012239 silicon dioxide Nutrition 0.000 description 9
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
238000004587 chromatography analysis Methods 0.000 description 8
239000012153 distilled water Substances 0.000 description 8
229910052943 magnesium sulfate Inorganic materials 0.000 description 8
235000019341 magnesium sulphate Nutrition 0.000 description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
239000011541 reaction mixture Substances 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 7
238000007327 hydrogenolysis reaction Methods 0.000 description 7
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 6
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
239000008346 aqueous phase Substances 0.000 description 6
238000010828 elution Methods 0.000 description 6
230000032050 esterification Effects 0.000 description 6
238000005886 esterification reaction Methods 0.000 description 6
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
238000007127 saponification reaction Methods 0.000 description 6
235000017557 sodium bicarbonate Nutrition 0.000 description 6
229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
239000002904 solvent Substances 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
YWLXLRUDGLRYDR-SKXCCXORSA-N 10-dab iii Chemical compound O([C@H]1C2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-SKXCCXORSA-N 0.000 description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
230000002159 abnormal effect Effects 0.000 description 5
230000009471 action Effects 0.000 description 5
229910052786 argon Inorganic materials 0.000 description 5
239000002585 base Substances 0.000 description 5
238000009835 boiling Methods 0.000 description 5
239000003054 catalyst Substances 0.000 description 5
238000010908 decantation Methods 0.000 description 5
239000001257 hydrogen Substances 0.000 description 5
229910052739 hydrogen Inorganic materials 0.000 description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
230000001575 pathological effect Effects 0.000 description 5
LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
229910052783 alkali metal Inorganic materials 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
230000004663 cell proliferation Effects 0.000 description 4
239000000460 chlorine Substances 0.000 description 4
229910052801 chlorine Inorganic materials 0.000 description 4
230000008878 coupling Effects 0.000 description 4
238000010168 coupling process Methods 0.000 description 4
238000005859 coupling reaction Methods 0.000 description 4
229960004679 doxorubicin Drugs 0.000 description 4
239000011521 glass Substances 0.000 description 4
NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 4
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 4
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 4
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
238000006136 alcoholysis reaction Methods 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000007900 aqueous suspension Substances 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000011734 sodium Substances 0.000 description 3
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 2
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
108090000704 Tubulin Proteins 0.000 description 2
102000004243 Tubulin Human genes 0.000 description 2
150000001241 acetals Chemical class 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
229910001508 alkali metal halide Inorganic materials 0.000 description 2
150000008045 alkali metal halides Chemical class 0.000 description 2
229910000318 alkali metal phosphate Inorganic materials 0.000 description 2
150000001350 alkyl halides Chemical class 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
239000012300 argon atmosphere Substances 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
239000000969 carrier Substances 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000003974 emollient agent Substances 0.000 description 2
150000002118 epoxides Chemical class 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
230000036457 multidrug resistance Effects 0.000 description 2
150000004767 nitrides Chemical class 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
239000011698 potassium fluoride Substances 0.000 description 2
235000003270 potassium fluoride Nutrition 0.000 description 2
238000012746 preparative thin layer chromatography Methods 0.000 description 2
150000003242 quaternary ammonium salts Chemical class 0.000 description 2
230000004044 response Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
235000009518 sodium iodide Nutrition 0.000 description 2
238000003756 stirring Methods 0.000 description 2
150000003512 tertiary amines Chemical class 0.000 description 2
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 2
WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
239000008096 xylene Substances 0.000 description 2
150000003738 xylenes Chemical class 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
HAKRSIFCTAKBRD-TYFJVFSVSA-N (8s,9s,10r,13s,14s,17s)-17-acetyl-1-methoxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1C[C@@H]2[C@@]3(C)C(OC)CC(=O)C=C3CC[C@H]2[C@@H]2CC[C@H](C(C)=O)[C@]21C HAKRSIFCTAKBRD-TYFJVFSVSA-N 0.000 description 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
229940005561 1,4-benzoquinone Drugs 0.000 description 1
102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 1
LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
150000007579 7-membered cyclic compounds Chemical class 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
208000006332 Choriocarcinoma Diseases 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
102000029749 Microtubule Human genes 0.000 description 1
108091022875 Microtubule Proteins 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
240000007817 Olea europaea Species 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
241001116500 Taxus Species 0.000 description 1
241001116498 Taxus baccata Species 0.000 description 1
235000009065 Taxus cuspidata Nutrition 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
208000008383 Wilms tumor Diseases 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
125000005107 alkyl diaryl silyl group Chemical group 0.000 description 1
229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
150000008052 alkyl sulfonates Chemical class 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229960003437 aminoglutethimide Drugs 0.000 description 1
ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
150000004200 baccatin III derivatives Chemical class 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
244000309464 bull Species 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
235000013877 carbamide Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
229960005243 carmustine Drugs 0.000 description 1
ITZXULOAYIAYNU-UHFFFAOYSA-N cerium(4+) Chemical compound [Ce+4] ITZXULOAYIAYNU-UHFFFAOYSA-N 0.000 description 1
230000008859 change Effects 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
208000006990 cholangiocarcinoma Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000006704 dehydrohalogenation reaction Methods 0.000 description 1
125000005105 dialkylarylsilyl group Chemical group 0.000 description 1
MVLMPMUGCWJDLE-UHFFFAOYSA-M dibutylboron trifluoromethanesulfonate Chemical compound [O-]S(=O)(=O)C(F)(F)F.CCCC[B+]CCCC MVLMPMUGCWJDLE-UHFFFAOYSA-M 0.000 description 1
YVHPHQBRUPLYOS-UHFFFAOYSA-N dichloromethane;methane Chemical compound C.ClCCl YVHPHQBRUPLYOS-UHFFFAOYSA-N 0.000 description 1
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
229960000452 diethylstilbestrol Drugs 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
229960002568 ethinylestradiol Drugs 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
229960001751 fluoxymesterone Drugs 0.000 description 1
150000002224 folic acids Chemical class 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
150000002466 imines Chemical class 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960004961 mechlorethamine Drugs 0.000 description 1
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
229960004296 megestrol acetate Drugs 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
210000004688 microtubule Anatomy 0.000 description 1
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
229960000350 mitotane Drugs 0.000 description 1
239000003607 modifier Substances 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
239000005445 natural material Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
125000003884 phenylalkyl group Chemical group 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229960003171 plicamycin Drugs 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
229960000624 procarbazine Drugs 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
230000003439 radiotherapeutic effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
210000005227 renal system Anatomy 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000010956 selective crystallization Methods 0.000 description 1
229960003440 semustine Drugs 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
229940063683 taxotere Drugs 0.000 description 1
229960001278 teniposide Drugs 0.000 description 1
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
229960001712 testosterone propionate Drugs 0.000 description 1
DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
238000005979 thermal decomposition reaction Methods 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
229960003087 tioguanine Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
125000004665 trialkylsilyl group Chemical group 0.000 description 1
125000005106 triarylsilyl group Chemical group 0.000 description 1
150000004654 triazenes Chemical class 0.000 description 1
230000001173 tumoral effect Effects 0.000 description 1
150000003672 ureas Chemical class 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Epoxy Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO19952264A 1992-12-09 1995-06-08 Nye taxoider, deres fremstilling og farmasöytiske preparater inneholdende taxoidene NO310555B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9214813A FR2698871B1 (fr)	1992-12-09	1992-12-09	Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
PCT/FR1993/001201 WO1994013654A1 (fr)	1992-12-09	1993-12-07	Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent

Publications (3)

Publication Number	Publication Date
NO952264D0 NO952264D0 (no)	1995-06-08
NO952264L NO952264L (no)	1995-06-08
NO310555B1 true NO310555B1 (no)	2001-07-23

Family

ID=9436375

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19952264A NO310555B1 (no)	1992-12-09	1995-06-08	Nye taxoider, deres fremstilling og farmasöytiske preparater inneholdende taxoidene

Country Status (30)

Country	Link
US (9)	US7074821B1 (bg)
EP (1)	EP0673372B1 (bg)
JP (2)	JP2785248B2 (bg)
KR (1)	KR100346328B1 (bg)
CN (1)	CN1055467C (bg)
AT (1)	ATE243688T1 (bg)
AU (2)	AU685415B2 (bg)
BG (1)	BG61726B1 (bg)
BR (1)	BR9307613A (bg)
CA (1)	CA2150944C (bg)
CZ (1)	CZ289851B6 (bg)
DE (1)	DE69333064T2 (bg)
DK (1)	DK0673372T3 (bg)
ES (1)	ES2202319T3 (bg)
FI (1)	FI110941B (bg)
FR (1)	FR2698871B1 (bg)
HU (1)	HU227872B1 (bg)
MX (1)	MX9307748A (bg)
NO (1)	NO310555B1 (bg)
NZ (1)	NZ258592A (bg)
OA (1)	OA10166A (bg)
PL (3)	PL175111B1 (bg)
PT (1)	PT673372E (bg)
RO (1)	RO112281B1 (bg)
RU (1)	RU2139864C1 (bg)
SG (1)	SG67338A1 (bg)
SK (1)	SK282139B6 (bg)
TW (1)	TW408120B (bg)
UA (1)	UA51612C2 (bg)
WO (1)	WO1994013654A1 (bg)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2696460B1 (fr) *	1992-10-05	1994-11-25	Rhone Poulenc Rorer Sa	Procédé de préparation de dérivés du taxane.
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
FR2698361B1 (fr) *	1992-11-20	1995-01-13	Rhone Poulenc Rorer Sa	Procédé de préparation d'un acide oxazolidine-1,3 carboxylique-5.
FR2698871B1 (fr) *	1992-12-09	1995-02-24	Rhone Poulenc Rorer Sa	Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5814658A (en)	1992-12-09	1998-09-29	Rhone-Poulenc Rorer S.A.	Taxoids, their preparation and pharmaceutical compositions containing them
IL107950A (en)	1992-12-15	2001-04-30	Upjohn Co	b 7, b 8 - Matano - Taxols, their preparation and pharmaceutical preparations against malignant tumors containing them
US5973160A (en) *	1992-12-23	1999-10-26	Poss; Michael A.	Methods for the preparation of novel sidechain-bearing taxanes
EP0982301B1 (en) *	1993-06-11	2003-09-10	PHARMACIA & UPJOHN COMPANY	Delta 6,7-taxols antineoplastic use and pharmaceutical compositions containing them
FR2706457B1 (fr) *	1993-06-16	1995-07-28	Rhone Poulenc Rorer Sa	Procédé de préparation d'un acide oxazolidinecarboxylique utile pour préparer des taxoïdes thérapeutiquement actifs.
FR2712288B1 (fr) *	1993-11-08	1996-01-05	Rhone Poulenc Rorer Sa	Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
IL127598A (en) *	1994-01-28	2003-04-10	Upjohn Co	Process for preparing isotaxol analogs
FR2721023B1 (fr) *	1994-06-09	1996-07-12	Rhone Poulenc Rorer Sa	Nouveaux Taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2721024B1 (fr) *	1994-06-09	1996-07-12	Rhone Poulenc Rorer Sa	Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2726272B1 (fr) *	1994-10-26	1996-12-06	Rhone Poulenc Rorer Sa	Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
CA2170661A1 (en) *	1995-03-22	1996-09-23	John K. Thottathil	Novel methods for the preparation of taxanes using oaxzolidine intermediates
FR2732342B1 (fr) *	1995-04-03	1997-04-30	Rhone Poulenc Rorer Sa	Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2732968B1 (fr) *	1995-04-14	1997-05-16	Rhone Poulenc Rorer Sa	Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2742438B1 (fr) *	1995-12-14	1998-01-16	Rhone Poulenc Rorer Sa	Dihydrate du (2r,3s)-3-tert-butoxycarbonylamino-2-hydroxy- 3-phenylpropionate de 4,10beta-diacetoxy-2alpha-benzoyloxy- 5beta,2o-epoxy-1-hydroxy-9-oxo-19-nor-cyclopropa(g)tax-11- ene-13alpha-yle, et son procede de preparation
FR2742357B1 (fr) *	1995-12-19	1998-01-09	Rhone Poulenc Rorer Sa	Nanoparticules stabilisees et filtrables dans des conditions steriles
FR2742753B1 (fr) *	1995-12-22	1998-01-30	Rhone Poulenc Rorer Sa	Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
WO1997044026A1 (en) *	1996-05-22	1997-11-27	Neuromedica, Inc.	Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
US5919815A (en) *	1996-05-22	1999-07-06	Neuromedica, Inc.	Taxane compounds and compositions
US5795909A (en) *	1996-05-22	1998-08-18	Neuromedica, Inc.	DHA-pharmaceutical agent conjugates of taxanes
AU737078C (en)	1996-05-24	2002-05-02	Angiotech Pharmaceuticals, Inc.	Compositions and methods for treating or preventing diseases of body passageways
FR2750989B1 (fr) *	1996-07-09	1998-09-25	Rhone Poulenc Rorer Sa	Procede de monoacylation d'hydroxy taxanes
US5773464A (en) *	1996-09-30	1998-06-30	Bristol-Myers Squibb Company	C-10 epoxy taxanes
AU4768797A (en)	1996-10-24	1998-05-15	Institute Armand-Frappier	A family of canadensol taxanes, the semi-synthetic preparation and therapeutic use thereof
US6515016B2 (en)	1996-12-02	2003-02-04	Angiotech Pharmaceuticals, Inc.	Composition and methods of paclitaxel for treating psoriasis
US20030157187A1 (en) *	1996-12-02	2003-08-21	Angiotech Pharmaceuticals, Inc.	Compositions and methods for treating or preventing inflammatory diseases
US6495579B1 (en)	1996-12-02	2002-12-17	Angiotech Pharmaceuticals, Inc.	Method for treating multiple sclerosis
WO1998049321A2 (en) *	1997-04-28	1998-11-05	Rhone-Poulenc Rorer S.A.	Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
US7288665B1 (en)	1997-08-18	2007-10-30	Florida State University	Process for selective derivatization of taxanes
US6111144A (en)	1997-08-21	2000-08-29	Florida State University	Method for the synthesis of a taxane intermediate
US6831057B2 (en) *	1997-10-28	2004-12-14	The University Of North Carolina At Chapel Hill	Use of NF-κB inhibition in combination therapy for cancer
US6150537A (en) *	1997-12-12	2000-11-21	Emory University	Methods for the esterification of alcohols and compounds useful therefor as potential anticancer agents
AU741143B2 (en) *	1998-01-14	2001-11-22	Bristol-Myers Squibb Company	Novel crystalline complexes of baccatin III with imidazole, 2-methylimidazole or isopropanol
US6156789A (en) *	1998-03-17	2000-12-05	Rhone-Poulenc Rorer S.A.	Method for treating abnormal cell proliferation in the brain
US6391911B1 (en) *	1999-02-26	2002-05-21	Robert E. Bases	Coadministration of lucanthone and radiation for treatment of cancer
US7235583B1 (en)	1999-03-09	2007-06-26	Luitpold Pharmaceuticals, Inc.,	Fatty acid-anticancer conjugates and uses thereof
CA2365776A1 (en) *	1999-05-03	2000-11-09	Alain Renard	Method for treating abnormal cell proliferation in the brain
FR2794771B1 (fr)	1999-06-11	2001-08-10	Aventis Pharma Sa	Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
EP1229934B1 (en)	1999-10-01	2014-03-05	Immunogen, Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CA2410632A1 (en)	2000-06-22	2001-12-27	David S. Garvey	Nitrosated and nitrosylated taxanes, compositions and methods of use
EP1318794A2 (en)	2000-09-22	2003-06-18	Bristol-Myers Squibb Company	Method for reducing toxicity of combined chemotherapies
CA2501805C (en) *	2002-10-09	2012-05-22	Phytogen Life Sciences, Inc.	Novel taxanes and methods related to use and preparation thereof
US7787855B2 (en) *	2003-03-31	2010-08-31	Motorola, Inc.	Establishing emergency sessions in packet data networks for wireless devices having invalid subscriber identities
US6956124B2 (en)	2003-04-14	2005-10-18	Aventis Pharma S.A.	Process for the preparation of 4,10β-diacetoxy-2α-benzoyloxy-5β,20-epoxy-1,13α-dihydroxy-9-oxo-19-norcyclopropa[g]tax-11-ene
US7202370B2 (en) *	2003-10-27	2007-04-10	Conor Medsystems, Inc.	Semi-synthesis of taxane intermediates from 9-dihydro-13-acetylbaccatin III
CA2865410C (en) *	2005-11-18	2022-04-26	Mark Gelfand	System and method to modulate phrenic nerve to prevent sleep apnea
AU2007226937A1 (en) *	2006-03-21	2007-09-27	Dr. Reddy's Laboratories Ltd.	Docetaxel polymorphs and processes
CN100588643C (zh) *	2006-11-02	2010-02-10	南京航空航天大学	一种含有二取代金刚烷基的维甲酸类化合物制备方法
US20090076127A1 (en) *	2007-09-19	2009-03-19	Protia, Llc	Deuterium-enriched larotaxel
CN101863861A (zh) *	2009-04-16	2010-10-20	山东靶点药物研究有限公司	一种简便高效地制备紫杉醇类似物Larotaxel的方法
WO2011051894A1 (en)	2009-10-29	2011-05-05	Aventis Pharma S.A.	Novel antitumoral use of cabazitaxel
CA2798180A1 (en)	2010-05-03	2011-11-10	Teikoku Pharma Usa, Inc.	Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
ES2704632T3 (es)	2011-09-08	2019-03-19	Univ New York	Virus de herpes simplex oncolítico y sus usos terapéuticos
WO2013096455A1 (en)	2011-12-20	2013-06-27	Dana-Farber Cancer Institute, Inc.	Methods for diagnosing and treating oncogenic kras-associated cancer
EP2855698A4 (en)	2012-05-24	2016-03-30	Dana Farber Cancer Inst Inc	OBTAINING TO THE GLUTAMINE-TO-PYRUVAT SIGNAL PATH FOR THE TREATMENT OF CANCER ASSOCIATED WITH THE KRAS ONKOGEN
US20150285802A1 (en)	2012-07-18	2015-10-08	Dana-Farber Cancer Institute, Inc.	Methods for treating, preventing and predicting risk of developing breast cancer
JO3685B1 (ar)	2012-10-01	2020-08-27	Teikoku Pharma Usa Inc	صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US10238723B2 (en)	2013-03-14	2019-03-26	Icahn School Of Medicine At Mount Sinai	Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer
WO2015050844A1 (en)	2013-10-01	2015-04-09	Dana-Farber Cancer Institute, Inc.	Methods of treating cancer with atovaquone-related compounds
US10350264B2 (en)	2014-03-27	2019-07-16	Dana-Farber Cancer Institute, Inc.	Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin
MA39818A (fr)	2014-03-30	2017-02-08	Benevir Biopharm Inc	Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
WO2016205429A1 (en)	2015-06-15	2016-12-22	New York University	Method of treatment using oncolytic viruses
CN112574134A (zh) *	2020-12-30	2021-03-30	重庆市碚圣医药科技股份有限公司	一种多西紫杉醇侧链的合成方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US487399A (en) *		1892-12-06		Timepiece repeating mechanism
US4534899A (en)	1981-07-20	1985-08-13	Lipid Specialties, Inc.	Synthetic phospholipid compounds
US4507217A (en)	1983-03-07	1985-03-26	Lipid Specialties, Inc.	Magnetic compositions and magnetic memory devices prepared therefrom
FR2601676B1 (fr)	1986-07-17	1988-09-23	Rhone Poulenc Sante	Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr) *	1986-07-17	1988-09-23	Rhone Poulenc Sante	Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4876399A (en)	1987-11-02	1989-10-24	Research Corporation Technologies, Inc.	Taxols, their preparation and intermediates thereof
GB8806224D0 (en)	1988-03-16	1988-04-13	Johnson Matthey Plc	Platinum chemotherapeutic product
FR2629819B1 (fr)	1988-04-06	1990-11-16	Rhone Poulenc Sante	Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
MY110249A (en)	1989-05-31	1998-03-31	Univ Florida State	Method for preparation of taxol using beta lactam
US5175315A (en) *	1989-05-31	1992-12-29	Florida State University	Method for preparation of taxol using β-lactam
US5411947A (en)	1989-06-28	1995-05-02	Vestar, Inc.	Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5136060A (en)	1989-11-14	1992-08-04	Florida State University	Method for preparation of taxol using an oxazinone
US5015744A (en)	1989-11-14	1991-05-14	Florida State University	Method for preparation of taxol using an oxazinone
MX9102128A (es)	1990-11-23	1992-07-08	Rhone Poulenc Rorer Sa	Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
US5399363A (en)	1991-01-25	1995-03-21	Eastman Kodak Company	Surface modified anticancer nanoparticles
US5645988A (en)	1991-05-08	1997-07-08	The United States Of America As Represented By The Department Of Health And Human Services	Methods of identifying drugs with selective effects against cancer cells
AU2005692A (en)	1991-05-08	1992-12-21	United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer
US5698582A (en)	1991-07-08	1997-12-16	Rhone-Poulenc Rorer S.A.	Compositions containing taxane derivatives
US5714513A (en)	1991-09-23	1998-02-03	Florida State University	C10 taxane derivatives and pharmaceutical compositions
US5399726A (en)	1993-01-29	1995-03-21	Florida State University	Process for the preparation of baccatin III analogs bearing new C2 and C4 functional groups
US5710287A (en)	1991-09-23	1998-01-20	Florida State University	Taxanes having an amino substituted side-chain and pharmaceutical compositions containing them
US5350866A (en)	1991-09-23	1994-09-27	Bristol-Myers Squibb Company	10-desacetoxytaxol derivatives
US5489601A (en)	1991-09-23	1996-02-06	Florida State University	Taxanes having a pyridyl substituted side-chain and pharmaceutical compositions containing them
US5654447A (en)	1991-09-23	1997-08-05	Florida State University	Process for the preparation of 10-desacetoxybaccatin III
US5338872A (en)	1993-01-15	1994-08-16	Florida State University	Process for the preparation of 10-desacetoxybaccatin III and 10-desacetoxytaxol and derivatives thereof
US5739362A (en)	1991-09-23	1998-04-14	Florida State University	Taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them
US5721268A (en)	1991-09-23	1998-02-24	Florida State University	C7 taxane derivatives and pharmaceutical compositions containing them
US5274124A (en)	1991-09-23	1993-12-28	Florida State University	Metal alkoxides
US5284865A (en)	1991-09-23	1994-02-08	Holton Robert A	Cyclohexyl substituted taxanes and pharmaceutical compositions containing them
US5227400A (en)	1991-09-23	1993-07-13	Florida State University	Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them
US5430160A (en)	1991-09-23	1995-07-04	Florida State University	Preparation of substituted isoserine esters using β-lactams and metal or ammonium alkoxides
US5250683A (en)	1991-09-23	1993-10-05	Florida State University	Certain substituted taxanes and pharmaceutical compositions containing them
US5728850A (en)	1991-09-23	1998-03-17	Florida State University	Taxanes having a butenyl substituted side-chain and pharmaceutical compositions containing them
US5229526A (en)	1991-09-23	1993-07-20	Florida State University	Metal alkoxides
US5283253A (en)	1991-09-23	1994-02-01	Florida State University	Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
US5243045A (en)	1991-09-23	1993-09-07	Florida State University	Certain alkoxy substituted taxanes and pharmaceutical compositions containing them
US5728725A (en)	1991-09-23	1998-03-17	Florida State University	C2 taxane derivaties and pharmaceutical compositions containing them
US5262409A (en)	1991-10-11	1993-11-16	Fred Hutchinson Cancer Research Center	Binary tumor therapy
US5294737A (en)	1992-02-27	1994-03-15	The Research Foundation State University Of New York	Process for the production of chiral hydroxy-β-lactams and hydroxyamino acids derived therefrom
PT706373E (pt)	1992-03-23	2000-11-30	Univ Georgetown	Taxol encapsulado num liposoma e um metodo
US5254703A (en)	1992-04-06	1993-10-19	Florida State University	Semi-synthesis of taxane derivatives using metal alkoxides and oxazinones
US5254580A (en)	1993-01-19	1993-10-19	Bristol-Myers Squibb Company	7,8-cyclopropataxanes
US5294637A (en)	1992-07-01	1994-03-15	Bristol-Myers Squibb Company	Fluoro taxols
US5319112A (en)	1992-08-18	1994-06-07	Virgnia Tech Intellectual Properties, Inc.	Method for the conversion of cephalomannine to taxol and for the preparation of N-acyl analogs of taxol
FR2696459B1 (fr)	1992-10-05	1994-11-25	Rhone Poulenc Rorer Sa	Procédé de préparation de dérivés du taxane.
FR2697752B1 (fr)	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
FR2698871B1 (fr)	1992-12-09	1995-02-24	Rhone Poulenc Rorer Sa	Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5814658A (en)	1992-12-09	1998-09-29	Rhone-Poulenc Rorer S.A.	Taxoids, their preparation and pharmaceutical compositions containing them
IL107950A (en) *	1992-12-15	2001-04-30	Upjohn Co	b 7, b 8 - Matano - Taxols, their preparation and pharmaceutical preparations against malignant tumors containing them
CA2111527C (en)	1992-12-24	2000-07-18	Jerzy Golik	Phosphonooxymethyl ethers of taxane derivatives
ZA94128B (en)	1993-02-01	1994-08-19	Univ New York State Res Found	Process for the preparation of taxane derivatives and betalactam intermediates therefor
FR2703049B1 (fr)	1993-03-22	1995-04-21	Rhone Poulenc Rorer Sa	Procédé de purification des taxoïdes.
WO1994026254A1 (en)	1993-05-17	1994-11-24	The Liposome Company, Inc.	Incorporation of taxol into liposomes and gels
WO1994026253A1 (en)	1993-05-19	1994-11-24	The Liposome Company, Inc.	Liposome having a multicomponent bilayer which contains a bioactive agent as an integral component of the bilayer
US5405972A (en)	1993-07-20	1995-04-11	Florida State University	Synthetic process for the preparation of taxol and other tricyclic and tetracyclic taxanes
CA2129288C (en)	1993-08-17	2000-05-16	Jerzy Golik	Phosphonooxymethyl esters of taxane derivatives
FR2712288B1 (fr) *	1993-11-08	1996-01-05	Rhone Poulenc Rorer Sa	Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US6441026B1 (en)	1993-11-08	2002-08-27	Aventis Pharma S.A.	Antitumor compositions containing taxane derivatives
US5415869A (en)	1993-11-12	1995-05-16	The Research Foundation Of State University Of New York	Taxol formulation
FR2718963B1 (fr)	1994-04-25	1996-05-24	Rhone Poulenc Rorer Sa	Nouvelle composition pharmaceutique à base de taxoïdes.
DK0767786T3 (da)	1994-06-28	1999-06-14	Upjohn Co	7-ether-taxol-analoge, antineoplastisk anvendelse deraf og farmaceutiske præparater indeholdende disse forbindelser
FR2721928A1 (fr)	1994-07-04	1996-01-05	Rhone Poulenc Rorer Sa	Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
US6201140B1 (en)	1994-07-28	2001-03-13	Bristol-Myers Squibb Company	7-0-ethers of taxane derivatives
FR2726272B1 (fr)	1994-10-26	1996-12-06	Rhone Poulenc Rorer Sa	Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
US5635531A (en)	1996-07-08	1997-06-03	Bristol-Myers Squibb Company	3'-aminocarbonyloxy paclitaxels
US6156789A (en)	1998-03-17	2000-12-05	Rhone-Poulenc Rorer S.A.	Method for treating abnormal cell proliferation in the brain
EP0982028A1 (en)	1998-08-20	2000-03-01	Aventis Pharma S.A.	New use of taxoid derivatives

1992
- 1992-12-09 FR FR9214813A patent/FR2698871B1/fr not_active Expired - Lifetime
1993
- 1993-07-12 UA UA95062617A patent/UA51612C2/uk unknown
- 1993-12-07 WO PCT/FR1993/001201 patent/WO1994013654A1/fr active IP Right Grant
- 1993-12-07 RU RU95114534A patent/RU2139864C1/ru not_active IP Right Cessation
- 1993-12-07 PL PL93324755A patent/PL175111B1/pl unknown
- 1993-12-07 ES ES94901993T patent/ES2202319T3/es not_active Expired - Lifetime
- 1993-12-07 CZ CZ19951455A patent/CZ289851B6/cs not_active IP Right Cessation
- 1993-12-07 SG SG1996007594A patent/SG67338A1/en unknown
- 1993-12-07 BR BR9307613A patent/BR9307613A/pt not_active Application Discontinuation
- 1993-12-07 SK SK752-95A patent/SK282139B6/sk not_active IP Right Cessation
- 1993-12-07 JP JP6513859A patent/JP2785248B2/ja not_active Expired - Fee Related
- 1993-12-07 RO RO95-01107A patent/RO112281B1/ro unknown
- 1993-12-07 EP EP94901993A patent/EP0673372B1/fr not_active Expired - Lifetime
- 1993-12-07 AU AU56531/94A patent/AU685415B2/en not_active Expired
- 1993-12-07 DK DK94901993T patent/DK0673372T3/da active
- 1993-12-07 KR KR1019950702380A patent/KR100346328B1/ko not_active IP Right Cessation
- 1993-12-07 CA CA002150944A patent/CA2150944C/fr not_active Expired - Fee Related
- 1993-12-07 DE DE69333064T patent/DE69333064T2/de not_active Expired - Lifetime
- 1993-12-07 AT AT94901993T patent/ATE243688T1/de active
- 1993-12-07 NZ NZ258592A patent/NZ258592A/en not_active IP Right Cessation
- 1993-12-07 HU HU9501662A patent/HU227872B1/hu not_active IP Right Cessation
- 1993-12-07 PL PL93309293A patent/PL174830B1/pl unknown
- 1993-12-07 PL PL93324756A patent/PL175539B1/pl unknown
- 1993-12-07 PT PT94901993T patent/PT673372E/pt unknown
- 1993-12-08 US US08/162,984 patent/US7074821B1/en not_active Expired - Fee Related
- 1993-12-08 MX MX9307748A patent/MX9307748A/es unknown
- 1993-12-08 TW TW082110390A patent/TW408120B/zh not_active IP Right Cessation
- 1993-12-09 CN CN93121690A patent/CN1055467C/zh not_active Expired - Fee Related
1995
- 1995-06-07 US US08/483,697 patent/US5599942A/en not_active Expired - Lifetime
- 1995-06-07 US US08/479,198 patent/US5580997A/en not_active Expired - Fee Related
- 1995-06-07 US US08/487,232 patent/US5587493A/en not_active Expired - Lifetime
- 1995-06-07 US US08/475,621 patent/US5532388A/en not_active Expired - Fee Related
- 1995-06-07 US US08/483,693 patent/US5550261A/en not_active Expired - Lifetime
- 1995-06-07 US US08/479,199 patent/US5580998A/en not_active Expired - Lifetime
- 1995-06-07 US US08/474,551 patent/US5576450A/en not_active Expired - Fee Related
- 1995-06-07 US US08/474,417 patent/US5571917A/en not_active Expired - Lifetime
- 1995-06-08 FI FI952825A patent/FI110941B/fi not_active IP Right Cessation
- 1995-06-08 NO NO19952264A patent/NO310555B1/no not_active IP Right Cessation
- 1995-06-09 BG BG99713A patent/BG61726B1/bg unknown
- 1995-06-09 OA OA60675A patent/OA10166A/fr unknown
1997
- 1997-10-16 AU AU41870/97A patent/AU704663B2/en not_active Expired
1998
- 1998-02-19 JP JP10052669A patent/JPH10291930A/ja active Pending

Also Published As

Publication number	Publication date
CN1055467C (zh)	2000-08-16
US5532388A (en)	1996-07-02
BG99713A (bg)	1996-02-28
US5587493A (en)	1996-12-24
JP2785248B2 (ja)	1998-08-13
NO952264D0 (no)	1995-06-08
FI952825A0 (fi)	1995-06-08
UA51612C2 (uk)	2002-12-16
US5580997A (en)	1996-12-03
PL175111B1 (pl)	1998-11-30
FI110941B (fi)	2003-04-30
US5580998A (en)	1996-12-03
OA10166A (fr)	1996-12-18
SK75295A3 (en)	1995-11-08
AU685415B2 (en)	1998-01-22
AU5653194A (en)	1994-07-04
PT673372E (pt)	2003-11-28
CA2150944C (fr)	2004-02-24
US7074821B1 (en)	2006-07-11
HU227872B1 (en)	2012-05-29
KR950704287A (ko)	1995-11-17
CZ145595A3 (en)	1995-10-18
KR100346328B1 (ko)	2002-11-30
CA2150944A1 (fr)	1994-06-23
US5571917A (en)	1996-11-05
EP0673372A1 (fr)	1995-09-27
JPH10291930A (ja)	1998-11-04
PL309293A1 (en)	1995-10-02
DK0673372T3 (da)	2003-10-13
NZ258592A (en)	1996-12-20
NO952264L (no)	1995-06-08
ATE243688T1 (de)	2003-07-15
DE69333064T2 (de)	2004-08-19
EP0673372B1 (fr)	2003-06-25
US5576450A (en)	1996-11-19
US5550261A (en)	1996-08-27
RO112281B1 (ro)	1997-07-30
BG61726B1 (bg)	1998-04-30
FI952825A (fi)	1995-06-08
SK282139B6 (sk)	2001-11-06
CZ289851B6 (cs)	2002-04-17
ES2202319T3 (es)	2004-04-01
FR2698871A1 (fr)	1994-06-10
HUT73134A (en)	1996-06-28
TW408120B (en)	2000-10-11
FR2698871B1 (fr)	1995-02-24
AU704663B2 (en)	1999-04-29
RU2139864C1 (ru)	1999-10-20
PL175539B1 (pl)	1999-01-29
HU9501662D0 (en)	1995-08-28
DE69333064D1 (de)	2003-07-31
US5599942A (en)	1997-02-04
AU4187097A (en)	1998-01-08
SG67338A1 (en)	1999-09-21
JPH08504425A (ja)	1996-05-14
PL174830B1 (pl)	1998-09-30
CN1094720A (zh)	1994-11-09
WO1994013654A1 (fr)	1994-06-23
MX9307748A (es)	1994-06-30
BR9307613A (pt)	1999-05-25

Publication	Publication Date	Title
NO310555B1 (no)	2001-07-23	Nye taxoider, deres fremstilling og farmasöytiske preparater inneholdende taxoidene
JP2941951B2 (ja)	1999-08-30	新規なタキソイド、その製造及びそれを含有する製薬学的組成物
Samaranayake et al.	1991	Modified taxols. 5. Reaction of taxol with electrophilic reagents and preparation of a rearranged taxol derivative with tubulin assembly activity
US5847170A (en)	1998-12-08	Taxoids, their preparation and pharmaceutical compositions containing them
CZ294972B6 (cs)	2005-04-13	Taxoidy, meziprodukty pro jejich přípravu, způsoby přípravy taxoidů a farmaceutická kompozice tyto taxoidy obsahující
SK282162B6 (sk)	2001-11-06	Spôsob prípravy derivátov taxánu, deriváty taxánu, deriváty oxazolínu ako medziprodukty na prípravu derivátov taxánu a spôsob ich prípravy
US6194582B1 (en)	2001-02-27	Taxoids, their preparation and pharmaceutical compositions containing them
US5606083A (en)	1997-02-25	Process for the preparation of taxane derivatives, new derivatives thus obtained and the compositions which contain them
AU715228B2 (en)	2000-01-20	Taxoids, preparation thereof and pharmaceutical compositions containing same
CZ133696A3 (en)	1996-08-14	Novel taxoids, process of their preparation and pharmaceutical composition containing thereof
CZ287430B6 (en)	2000-11-15	Taxoids, process of their preparation and pharmaceutical composition in which said taxoids are comprised
US6156789A (en)	2000-12-05	Method for treating abnormal cell proliferation in the brain
CZ287649B6 (en)	2001-01-17	Taxoids, process of their preparation and pharmaceutical preparation in which they are comprised
FR2721023A1 (fr)	1995-12-15	Nouveaux Taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US6040466A (en)	2000-03-21	Taxoids, their preparation and pharmaceutical compositions containing them
JPH10500980A (ja)	1998-01-27	新規タキソイド類、その製造およびそれらを含む製薬学的組成物
FR2721025A1 (fr)	1995-12-15	Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.

Legal Events

Date	Code	Title	Description
2013-07-29	MM1K	Lapsed by not paying the annual fees